{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:34:36Z","timestamp":1791934476507,"version":"4.3.4"},"reference-count":249,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ijantimicag.2020.105906","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T21:49:19Z","timestamp":1579902559000},"page":"105906","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["Searching for drugs for Chagas disease, leishmaniasis and schistosomiasis: a review"],"prefix":"10.1016","volume":"55","author":[{"given":"Soraya Silva","family":"Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renan Vinicius","family":"de Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanine","family":"Giarolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar El","family":"Seoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Igne","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.105906_bib0001","unstructured":"Hudson Institute. Social and economic impact review on Neglected Tropical Diseases. 2012. Available from:https:\/\/www.hudson.org\/content\/researchattachments\/attachment\/1083\/social_and_economic_impact_review_on_neglected_tropical_diseases_hudson_institute_and_sabin_institute_november_2012.pdf. Accessed on April 18, 2019."},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0002","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(07)70209-8","article-title":"Cutaneous leishmaniasis","volume":"7","author":"Reithinger","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0003","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.2174\/138955708786369528","article-title":"Anti-T. cruzi agents: our experience in the evaluation of more than five hundred compounds","volume":"8","author":"Cerecetto","year":"2008","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0004","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/QCO.0b013e3283402956","article-title":"Advances in Chagas disease drug development: 2009-2010","volume":"23","author":"Buckner","year":"2010","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0005","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/jps.23010","article-title":"First century of Chagas' disease: an overview on novel approaches to nifurtimox and benzonidazole delivery systems","volume":"101","author":"Salomon","year":"2012","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0006","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.pt.2014.01.008","article-title":"Chagas disease: the challenge of polyparasitism?","volume":"30","author":"Perez","year":"2014","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0007","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.2174\/0929867322666151015120804","article-title":"Current and future chemotherapy for Chagas Disease","volume":"22","author":"Gaspar","year":"2015","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0008","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2217\/nnm.14.185","article-title":"Nanomedicines against Chagas disease: an update on therapeutics, prophylaxis and diagnosis","volume":"10","author":"Morilla","year":"2015","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0009","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1087057114550585","article-title":"Chagas disease drug discovery: toward a new era","volume":"20","author":"Chatelain","year":"2015","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0010","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2174\/138955751503150312122523","article-title":"Drug design for neglected disease in Brazil","volume":"15","author":"Giarolla","year":"2015","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0011","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1051\/parasite\/2014012","article-title":"Chagas disease in the 21st century: a public health success or an emerging threat?","volume":"21","author":"Bonney","year":"2014","journal-title":"Parasite"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0012","unstructured":"World Health Organization. 2018. Available from:http:\/\/www.who.int\/chagas\/epidemiology\/en\/. Accessed on September 23, 2018."},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0013","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1038\/nature09224","article-title":"Chagas disease: pushing through the pipeline","volume":"465","author":"Clayton","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0014","doi-asserted-by":"crossref","first-page":"16092","DOI":"10.1038\/nmicrobiol.2016.92","article-title":"Drug resistance in eukaryotic microorganisms","volume":"1","author":"Fairlamb","year":"2016","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0015","unstructured":"World Health Organization. Chagas disease (American trypanosomiasis). 2016. Available from:http:\/\/www.who.int\/mediacentre\/factsheets\/fs340\/en\/. Accessed on April 18, 2019."},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0016","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2174\/092986709787458489","article-title":"Leishmaniasis: current treatment and prospects for new drugs and vaccines","volume":"16","author":"Kedzierski","year":"2009","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0017","doi-asserted-by":"crossref","first-page":"10369","DOI":"10.1021\/cr400552x","article-title":"Fruitful decade for antileishmanial compounds from 2002 to late 2011","volume":"114","author":"Hussain","year":"2014","journal-title":"Chem Rev"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0018","unstructured":"World Health Organization. WHO Leishmaniasis control programme. Annual country reports. 2018. Available from:http:\/\/gamapserver.who.int\/mapLibrary\/app\/searchResults.aspx. Accessed on April 7, 2019."},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0019","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1016\/j.bmc.2017.04.031","article-title":"Medicinal chemistry of antischistosomal drugs: praziquantel and oxamniquine","volume":"25","author":"Silva","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0020","first-page":"1459","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the global burden of disease study 2015","volume":"88","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0021","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1056\/NEJMra012396","article-title":"Schistosomiasis","volume":"346","author":"Ross","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0022","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.trecan.2015.08.011","article-title":"Why does infection with some helminths cause cancer?","volume":"1","author":"Brindley","year":"2015","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0023","unstructured":"World Health Organization. 2018. Available from:http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/schistosomiasis. Accessed on September 23, 2018."},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0024","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nri843","article-title":"The immunobiology of schistosomiasis","volume":"2","author":"Pearce","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0025","unstructured":"Center for Disease Control and Prevention (CDC). Infectious Diseases Related to Travel. 2018. Available from:https:\/\/wwwnc.cdc.gov\/travel\/yellowbook\/2018\/infectious-diseases-related-to-travel\/schistosomiasis. Accessed on April 7, 2019."},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0026","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.2174\/1568026616666160413125049","article-title":"Stairway to heaven or hell? Perspectives and limitations of Chagas disease chemotherapy","volume":"16","author":"Salomao","year":"2016","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0027","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.2174\/1568026616666160413124902","article-title":"Advances and progress in Chagas Disease drug discovery","volume":"16","author":"Ferreira","year":"2016","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0028","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0029","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1590\/S0104-59701995000100004","article-title":"Chagas, the logic and the discovery","volume":"1","author":"Delaporte","year":"1994","journal-title":"Hist Cienc Saude Manguinhos"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0030","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1590\/S0074-02762011000600001","article-title":"Chronic phase of Chagas disease: why should it be treated? A comprehensive review","volume":"106","author":"Coura","year":"2011","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0031","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4331\/wjbc.v8.i1.57","article-title":"Challenges in the chemotherapy of Chagas disease: Looking for possibilities related to the differences and similarities between the parasite and host","volume":"8","author":"Sueth-Santiago","year":"2017","journal-title":"World J Biol Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0032","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.2174\/0929867323999160625124424","article-title":"Challenges in Chagas disease drug discovery: a review","volume":"23","author":"Paucar","year":"2016","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0033","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1073\/pnas.0711014105","article-title":"A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes","volume":"105","author":"Wilkinson","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0034","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1590\/S0074-02762002000100001","article-title":"A critical review on Chagas Disease chemotherapy","volume":"97","author":"Coura","year":"2002","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0035","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1056\/NEJMra1410150","article-title":"Chagas' Disease","volume":"373","author":"Bern","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0036","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1191\/0960327106het653oa","article-title":"Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis)","volume":"25","author":"Castro","year":"2006","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0037","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1128\/AAC.01662-13","article-title":"Towards a paradigm shift in the treatment of chronic Chagas disease","volume":"58","author":"Viotti","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0038","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.actatropica.2009.10.023","article-title":"Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches","volume":"115","author":"Urbina","year":"2010","journal-title":"Acta Trop"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0039","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1007\/s11095-011-0586-3","article-title":"Mitochondria and trypanosomatids: targets and drugs","volume":"28","author":"Fidalgo","year":"2011","journal-title":"Pharm Res"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0040","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1590\/S0074-02762009000900041","article-title":"Ergosterol biosynthesis and drug development for Chagas disease","volume":"104","author":"Urbina","year":"2009","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0041","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ijpddr.2011.12.002","article-title":"Recent developments in sterol 14\u03b1-demethylase inhibitors for Chagas disease","volume":"2","author":"Buckner","year":"2012","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0042","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.2174\/0929867322666150319120337","article-title":"Sterol biosynthesis pathway as an alternative for the anti-protozoan parasite chemotherapy","volume":"22","author":"Macedo-Silva","year":"2015","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0043","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/978-1-4419-8414-2_7","article-title":"Cruzain: the path from target validation to the clinic","volume":"712","author":"Sajid","year":"2011","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0044","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.2174\/0929867311320210005","article-title":"Trypanosomatidae diseases: from the current therapy to the efficacious role of trypanothione reductase in drug discovery","volume":"20","author":"Bernardes","year":"2013","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0045","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2174\/0929867320666131119122145","article-title":"Key proteins in the polyamine-trypanothione pathway as drug targets against Trypanosoma cruzi","volume":"21","author":"Maya","year":"2014","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0046","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.4155\/fmc.13.129","article-title":"Trypanosoma cruzi trans-sialidase as a drug target against Chagas disease (American trypanosomiasis)","volume":"5","author":"Miller","year":"2013","journal-title":"Future Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0047","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.4155\/fmc.13.166","article-title":"A pharmacophore-based virtual screening approach for the discovery of Trypanosoma cruzi GAPDH inhibitors","volume":"5","author":"Maluf","year":"2013","journal-title":"Future Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0048","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.2174\/09298673113209990139","article-title":"Glycosomal targets for anti-trypanosomatid drug discovery","volume":"21","author":"Barros-Alvarez","year":"2014","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0049","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1016\/j.bmc.2010.04.020","article-title":"Synthesis and characterization of potent inhibitors of Trypanosoma cruzi dihydrofolate reductase","volume":"18","author":"Schormann","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0050","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejmech.2015.04.028","article-title":"Design, synthesis and biological evaluation of quinazoline derivatives as anti-trypanosomatid and anti-plasmodial agents","volume":"96","author":"Mart\u00ednez","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0051","doi-asserted-by":"crossref","first-page":"135701","DOI":"10.4061\/2011\/135701","article-title":"Glucose-6-phosphate dehydrogenase of trypanosomatids: characterization, target validation, and drug discovery","volume":"2011","author":"Gupta","year":"2011","journal-title":"Mol Biol Int"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0052","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1177\/1087057114546896","article-title":"Discovery of new uncompetitive inhibitors of glucose-6-phosphate dehydrogenase","volume":"19","author":"Mercaldi","year":"2014","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0053","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/117739280700200007","article-title":"Trypanothione reductase: a viable chemotherapeutic target for antitrypanosomal and antileishmanial drug design","volume":"2","author":"Khan","year":"2007","journal-title":"Drug Target Insights"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0054","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1046\/j.1365-2958.2000.01721.x","article-title":"Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress","volume":"35","author":"Krieger","year":"2000","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0055","doi-asserted-by":"crossref","first-page":"e0003773","DOI":"10.1371\/journal.pntd.0003773","article-title":"Trypanothione reductase: a target protein for a combined in vitro and in silico screening approach","volume":"9","author":"Beig","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0056","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ijmm.2012.07.008","article-title":"The trypanothione system and its implications in the therapy of trypanosomatid diseases","volume":"302","author":"Floh\u00e9","year":"2012","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0057","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.actatropica.2015.02.012","article-title":"Trypanothione reductase inhibitors: overview of the action of thioridazine in different stages of Chagas disease","volume":"145","author":"Lo Presti","year":"2015","journal-title":"Acta Trop"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0058","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1021\/jm990386s","article-title":"Inhibition of Trypanosoma cruzi trypanothione reductase by acridines: kinetic studies and structure-activity relationships","volume":"42","author":"Bonse","year":"1999","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0059","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1042\/bj2860009","article-title":"Rationally designed selective inhibitors of trypanothione reductase. Phenothiazines and related tricyclics as lead structures","volume":"286","author":"Benson","year":"1992","journal-title":"Biochem J"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0060","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/cmdc.200900097","article-title":"Improved tricyclic inhibitors of trypanothione reductase by screening and chemical synthesis","volume":"4","author":"Richardson","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0061","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1021\/jm9603781","article-title":"A virtual screening approach applied to the search for trypanothione reductase inhibitors","volume":"40","author":"Horvath","year":"1997","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0062","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2174\/1568012033483006","article-title":"Central nervous system agents used as Trypanosoma cruzi infection chemotherapy: phenothiazines and related compounds","volume":"2","author":"Paglini-Oliva","year":"2003","journal-title":"Curr Med Chem Anti-Infect Agents"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0063","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0035-9203(01)90029-X","article-title":"Effects of clomipramine on Trypanosoma cruzi infection in mice","volume":"95","author":"Rivarola","year":"2001","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0064","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.exppara.2005.05.005","article-title":"Trypanosoma cruzi: chemotherapeutic effects of clomipramine in mice infected with an isolate obtained from an endemic area","volume":"111","author":"Rivarola","year":"2005","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0065","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/10715760100300311","article-title":"Trypanosoma cruzi trypanothione reductase is inactivated by peroxidase-generated phenothiazine cationic radicals","volume":"34","author":"Gutierrez-Correa","year":"2001","journal-title":"Free Radic Res"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0066","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1080\/00034983.1999.11813474","article-title":"Thioridazine treatment modifies the evolution of Trypanosoma cruzi infection in mice","volume":"93","author":"Rivarola","year":"1999","journal-title":"Ann Trop Med Parasitol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0067","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.ijantimicag.2003.10.006","article-title":"Thioridazine treatment prevents cardiopathy in Trypanosoma cruzi infected mice","volume":"23","author":"Lo Presti","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0068","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.2174\/1381612013397528","article-title":"The major cysteine proteinase of Trypanosoma cruzi: a valid target for chemotherapy of Chagas disease","volume":"7","author":"Cazzulo","year":"2001","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0069","doi-asserted-by":"crossref","first-page":"e1002139","DOI":"10.1371\/journal.ppat.1002139","article-title":"The Trypanosoma cruzi protease cruzain mediates immune evasion","volume":"7","author":"Doyle","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0070","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1590\/S0074-02762009000900034","article-title":"Two approaches to discovering and developing new drugs for Chagas disease","volume":"104","author":"McKerrow","year":"2009","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0071","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3762\/bjoc.9.3","article-title":"Chemical-biological characterization of a cruzain inhibitor reveals a second target and a mammalian off-target","volume":"9","author":"Choy","year":"2013","journal-title":"Beilstein J Org Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0072","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1128\/AAC.49.12.5160-5161.2005","article-title":"A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi","volume":"49","author":"Barr","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0073","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1021\/jm901633v","article-title":"Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for Chagas disease chemotherapy","volume":"53","author":"Brak","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0074","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.bmc.2017.02.009","article-title":"Synthesis and biological evaluation of potential inhibitors of the cysteine proteases cruzain and rhodesain designed by molecular simplification","volume":"25","author":"Braga","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actatropica.2015.12.017","article-title":"Current drug therapy and pharmaceutical challenges for Chagas disease","volume":"156","author":"Bermudez","year":"2016","journal-title":"Acta Trop"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0076","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1021\/jm00066a014","article-title":"Toward a novel metal-based chemotherapy against tropical diseases. 1. Enhancement of the efficacy of clotrimazole against Trypanosoma cruzi by complexation to ruthenium in RuCl2(clotrimazole)","volume":"36","author":"S\u00e1nchez-Delgado","year":"1993","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0077","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jinorgbio.2012.08.024","article-title":"Activity on Trypanosoma cruzi, erythrocytes lysis and biologically relevant physicochemical properties of Pd(II) and Pt(II) complexes of thiosemicarbazones derived from 1-indanones","volume":"117","author":"Santos","year":"2012","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0078","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s12011-013-9653-4","article-title":"Potential mechanism of the anti-trypanosomal activity of organoruthenium complexes with bioactive thiosemicarbazones","volume":"153","author":"Demoro","year":"2013","journal-title":"Biol Trace Elem Res"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0079","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ejmech.2016.05.003","article-title":"Gold (III) complexes with ONS-tridentate thiosemicarbazones: toward selective trypanocidal drugs","volume":"120","author":"Rettondin","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0080","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3389\/fmicb.2016.00348","article-title":"Role of Trypanosoma cruzi trans-sialidase on the escape from host immune surveillance","volume":"7","author":"Nardy","year":"2016","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0081","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1096\/fasebj.7.13.8405811","article-title":"Trans-sialidase: a unique enzyme activity discovered in the protozoan Trypanosoma cruzi","volume":"7","author":"Colli","year":"1993","journal-title":"FASEB J"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0082","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.carres.2011.04.006","article-title":"Trans-sialidase and mucins of Trypanosoma cruzi: an important interplay for the parasite","volume":"346","author":"Giorgi","year":"2011","journal-title":"Carbohydr Res"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0083","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.bmc.2009.12.062","article-title":"Potent inhibitor scaffold against Trypanosoma cruzi trans-sialidase","volume":"18","author":"Arioka","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0084","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0166-6851(02)00206-2","article-title":"Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania mexicana","volume":"125","author":"Urbina","year":"2002","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0085","doi-asserted-by":"crossref","first-page":"960","DOI":"10.4269\/ajtmh.1983.32.960","article-title":"Ketoconazole protects against infection Trypanosoma cruzi in a murine model","volume":"32","author":"McCabe","year":"1983","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0086","doi-asserted-by":"crossref","first-page":"9091","DOI":"10.1021\/bi034663f","article-title":"Conservation in the CYP51 family. Role of the B' helix\/BC loop and helices F and G in enzymatic function","volume":"42","author":"Lepesheva","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0087","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1074\/jbc.M510317200","article-title":"CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B' helix defines substrate preferences of sterol 14alpha-demethylase","volume":"281","author":"Lepesheva","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0088","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1590\/S0100-40422009000900038","article-title":"Quimioterapia da doen\u00e7a de Chagas: estado da arte e perspectivas no desenvolvimento de novos f\u00e1rmacos","volume":"32","author":"Dias","year":"2009","journal-title":"Qu\u00edm Nova"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0089","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0035-9203(87)90430-5","article-title":"Ketoconazole promotes parasitological cure of mice infected with Trypanosoma cruzi","volume":"81","author":"McCabe","year":"1987","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0090","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/infdis\/jit042","article-title":"VNI cures acute and chronic experimental Chagas disease","volume":"208","author":"Villalta","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0091","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/bs.pmch.2014.12.001","article-title":"A new era for Chagas disease drug discovery?","volume":"54","author":"Keenan","year":"2015","journal-title":"Prog Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0092","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/jeu.12184","article-title":"Recent clinical trials for the etiological treatment of chronic Chagas disease: advances, challenges and perspectives","volume":"62","author":"Urbina","year":"2015","journal-title":"J Eukaryot Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0093","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1038\/srep04703","article-title":"Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development","volume":"4","author":"Moraes","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0094","series-title":"Different Aspects on Chemotherapy of Trypanosomatids","first-page":"181","article-title":"Recent advances in drug development for Chagas disease: two magic words, combination and repositioning","author":"Salom\u00e3o","year":"2017"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0095","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1128\/AAC.06244-11","article-title":"Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib","volume":"56","author":"Buckner","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0096","doi-asserted-by":"crossref","first-page":"e923","DOI":"10.1371\/journal.pntd.0000923","article-title":"Fexinidazole\u2013a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness","volume":"4","author":"Torreele","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0097","doi-asserted-by":"crossref","first-page":"e1870","DOI":"10.1371\/journal.pntd.0001870","article-title":"Fexinidazole: a potential new drug candidate for Chagas disease","volume":"6","author":"Bahia","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0098","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/mutage\/ges015","article-title":"Genotoxicity profile of fexinidazole - a drug candidate in clinical development for human African trypanomiasis (sleeping sickness)","volume":"27","author":"Tweats","year":"2012","journal-title":"Mutagenesis"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0099","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1017\/S0031182010001137","article-title":"Chemotherapy against human African trypanosomiasis: is there a road to success?","volume":"137","author":"Burri","year":"2010","journal-title":"Parasitology"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0100","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1128\/AAC.00246-11","article-title":"Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness","volume":"55","author":"Kaiser","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0101","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1126\/scitranslmed.3003326","article-title":"The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis","volume":"4","author":"Wyllie","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0102","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1128\/AAC.01788-12","article-title":"Assessing the essentiality of Leishmania donovani nitroreductase and its role in nitro drug activation","volume":"57","author":"Wyllie","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0103","first-page":"1","article-title":"Therapeutic responses to different anti-Trypanosoma cruzi drugs in experimental infection by benznidazole-resistant parasite stock","volume":"21","author":"Caldas","year":"2014","journal-title":"Parasitology"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0104","series-title":"Fexinidazole. Drugs for Neglected Diseases initiative","year":"2018"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0105","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1016\/j.bmc.2003.07.004","article-title":"Synthesis and in vitro evaluation of potential antichagasic hydroxymethylnitrofurazone (NFOH-121): a new nitrofurazone prodrug","volume":"11","author":"Chung","year":"2003","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0106","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1128\/AAC.01451-09","article-title":"Hydroxymethylnitrofurazone is active in a murine model of Chagas' disease","volume":"54","author":"Davies","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0107","first-page":"319","article-title":"Diminui\u00e7\u00e3o da atividade mutag\u00eanica do pr\u00f3-f\u00e1rmaco NFOH-121 em rela\u00e7\u00e3o ao nitrofural (nitrofurazona)","volume":"22","author":"Guido","year":"2001","journal-title":"Rev Ci\u00eanc Farm"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0108","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/iep.12289","article-title":"Hydroxymethylnitrofurazone treatment in indeterminate form of chronic Chagas disease: reduced intensity of tissue parasitism and inflammation - a histopathological study","volume":"99","author":"Scarim","year":"2018","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0109","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/clpt.2012.236","article-title":"Phenotypic vs. target-based drug discovery for first-in-class medicines","volume":"93","author":"Swinney","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0110","doi-asserted-by":"crossref","first-page":"7727","DOI":"10.1021\/jm4004279","article-title":"Approaches to protozoan drug discovery: phenotypic screening","volume":"56","author":"Sykes","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0111","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1021\/jm500018m","article-title":"Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity","volume":"57","author":"Alvarez","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0112","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ejmech.2016.03.036","article-title":"Antichagasic and trichomonacidal activity of 1-substituted 2-benzyl-5-nitroindazolin-3-ones and 3-alkoxy-2-benzyl-5-nitro-2H-indazoles","volume":"115","author":"Berzal","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0113","doi-asserted-by":"crossref","first-page":"6467","DOI":"10.1016\/j.bmc.2015.08.014","article-title":"Discovery of potent nitrotriazole-based antitrypanosomal agents: in vitro and in vivo evaluation","volume":"23","author":"Papadopoulou","year":"2015","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0114","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa1313122","article-title":"Randomized trial of posaconazole and benznidazole for chronic Chagas\u2019 disease","volume":"370","author":"Molina","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0115","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ijantimicag.2012.08.002","article-title":"Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome\u00ae in mice infected with Trypanosoma cruzi strains","volume":"40","author":"Cencig","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0116","unstructured":"ClinicalTrials, gov. A study of the use of oral posaconazole (POS) in the treatment of asymptomatic chronic Chagas disease (P05267) (STOP CHAGAS), (n.d.). 2018. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01377480. Accessed on November 24, 2018."},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0117","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/B978-0-12-385863-4.00005-8","article-title":"Experimental chemotherapy and approaches to drug discovery for Trypanosoma cruzi infection","volume":"75","author":"Buckner","year":"2011","journal-title":"Adv Parasitol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0118","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.csbj.2016.12.002","article-title":"Chagas disease research and development: Is there light at the end of the tunnel?","volume":"15","author":"Chatelain","year":"2017","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0119","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrmicro.2016.193","article-title":"Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need","volume":"15","author":"Field","year":"2017","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0120","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1128\/AAC.00404-07","article-title":"Role of the ABC transporter PRP1 (ABCC7) in pentamidine resistance in Leishmania amastigotes","volume":"51","author":"Coelho","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0121","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa021556","article-title":"Oral miltefosine for Indian visceral leishmaniasis","volume":"347","author":"Sundar","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0122","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1086\/383321","article-title":"Miltefosine for new world cutaneous leishmaniasis","volume":"38","author":"Soto","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0123","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1371\/journal.pntd.0000912","article-title":"Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial","volume":"4","author":"Machado","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0124","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1128\/AAC.01319-08","article-title":"Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB\/c mice","volume":"53","author":"Jaafari","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0125","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/08982100903015025","article-title":"Topical delivery and in vivo antileishmanial activity of paromomycin-loaded liposomes for treatment of cutaneous leishmaniasis","volume":"20","author":"Carneiro","year":"2010","journal-title":"J Liposome Res"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0126","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3109\/08982104.2012.762519","article-title":"Development of liposomes loaded with anti-leishmanial drugs for the treatment of cutaneous leishmaniasis","volume":"23","author":"Momeni","year":"2013","journal-title":"J Liposome Res"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0127","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/dth.12357","article-title":"Topical liposomal azithromycin in the treatment of acute cutaneous leishmaniasis","volume":"29","author":"Rajabi","year":"2016","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0128","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1590\/S0036-46652004000300011","article-title":"Azithromycin in the treatment of mucosal leishmaniasis","volume":"46","author":"Silva-Vergara","year":"2004","journal-title":"Rev Inst Med Trop S\u00e3o Paulo"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0129","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/j.1365-4632.2006.02885.x","article-title":"Azithromycin, ineffective in the treatment of old-world cutaneous leishmaniasis","volume":"45","author":"Daoud","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0130","doi-asserted-by":"crossref","first-page":"640","DOI":"10.4269\/ajtmh.2007.77.640","article-title":"A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis","volume":"77","author":"Krolewiecki","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0131","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrmicro1748","article-title":"Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?","volume":"5","author":"Chappuis","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0132","doi-asserted-by":"crossref","first-page":"e584","DOI":"10.1371\/journal.pntd.0000584","article-title":"Control of visceral leishmaniasis in latin america-a systematic review","volume":"4","author":"Romero","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0133","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.2174\/092986712799828300","article-title":"Leishmaniasis: prevention, parasite detection and treatment","volume":"19","author":"Kobets","year":"2012","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0134","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00436-011-2680-1","article-title":"Diagnosis of visceral leishmaniasis: developments over the last decade","volume":"110","author":"Srividya","year":"2012","journal-title":"Parasitol Res"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0135","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.idc.2012.03.005","article-title":"Visceral leishmaniasis","volume":"26","author":"Van Griensven","year":"2012","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0136","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1016\/j.vaccine.2012.03.068","article-title":"Leishmaniasis: vaccine candidates and perspectives","volume":"30","author":"Singh","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0137","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3389\/fimmu.2014.00260","article-title":"Leishmania spp. proteome data sets: a comprehensive resource for vaccine development to target visceral leishmaniasis","volume":"5","author":"Aebischer","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0138","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.2174\/1381612821666141231163053","article-title":"Treatment of leishmaniasis: a review and assessment of recent research","volume":"21","author":"Elmahallawy","year":"2015","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0139","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3855\/jidc.6833","article-title":"Recent updates and perspectives on leishmaniasis","volume":"9","author":"Savoia","year":"2015","journal-title":"J Infect Dev Ctries"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0140","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.parint.2014.07.008","article-title":"Carbon nanotube based betulin formulation shows better efficacy against Leishmania parasite","volume":"63","author":"Saudagar","year":"2014","journal-title":"Parasitol Int"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0141","doi-asserted-by":"crossref","first-page":"11467","DOI":"10.1021\/ja803036e","article-title":"Targeted single-wall carbon nanotube mediated Pt (IV) prodrug delivery using folate as a homing device","volume":"130","author":"Dhar","year":"2008","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0142","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/jac\/dku422","article-title":"Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis","volume":"70","author":"Gupta","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0143","series-title":"DNDi-0690. Drugs for Neglected Diseases initiative","year":"2018"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0144","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/jac\/dkv376","article-title":"Nitroheterocyclic drug resistance mechanisms in Trypanosoma brucei","volume":"71","author":"Wyllie","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0145","series-title":"DNDi-6148. Drugs for Neglected Diseases initiative","year":"2018"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0146","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature19339","article-title":"Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness","volume":"537","author":"Khare","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0147","doi-asserted-by":"crossref","first-page":"00048","DOI":"10.1128\/CMR.00048-18","article-title":"Recent development of visceral leishmaniasis treatments: successes, pitfalls, and perspectives","volume":"31","author":"Alves","year":"2018","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0148","doi-asserted-by":"crossref","first-page":"9615","DOI":"10.1021\/acs.jmedchem.5b01456","article-title":"Novel amino-pyrazole ureas with potent in vitro and in vivo antileishmanial activity","volume":"58","author":"Mowbray","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0149","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2741\/4629","article-title":"Leishmaniasis treatment: update of possibilities for drug repurposing","volume":"23","author":"Andrade-Neto","year":"2018","journal-title":"Front Biosci"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0150","doi-asserted-by":"crossref","first-page":"e0004300","DOI":"10.1371\/journal.pntd.0004300","article-title":"A multilayer network approach for guiding drug repositioning in neglected diseases","volume":"10","author":"Berenstein","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0151","doi-asserted-by":"crossref","first-page":"e09744","DOI":"10.7554\/eLife.09744","article-title":"The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis","volume":"5","author":"Patterson","year":"2016","journal-title":"eLife"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0152","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1051\/parasite\/2011182115","article-title":"Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance","volume":"18","author":"Loiseau","year":"2011","journal-title":"Parasite"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0153","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.colsurfb.2015.04.013","article-title":"Therapeutic efficacy of artemisinin-loaded nanoparticles in experimental visceral leishmaniasis","volume":"130","author":"Want","year":"2015","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0154","first-page":"258","article-title":"Evaluation of apoptotic and antileishmanial activities of artemisinin on promastigotes and BALB\/C mice infected with Leishmania major","volume":"10","author":"Ghaffarifar","year":"2015","journal-title":"Iran J Parasitol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0155","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1099\/jmm.0.058115-0","article-title":"Activity of antimalarial drugs in vitro and in a murine model of cutaneous leishmaniasis","volume":"62","author":"Rocha","year":"2013","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0156","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1016\/j.bmc.2006.11.024","article-title":"Synthesis of isoquinuclidine analogs of chloroquine: antimalarial and antileishmanial activity","volume":"15","author":"Khan","year":"2007","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0157","first-page":"1467","article-title":"Imipramine alters the sterol profile in Leishmania amazonensis and increases its sensitivity to miconazole","volume":"183","author":"Andrade-Neto","year":"2016","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0158","doi-asserted-by":"crossref","first-page":"e1987","DOI":"10.1371\/journal.pntd.0001987","article-title":"Imipramine is an orally active drug against both antimony sensitive and resistant Leishmania donovani clinical isolates in experimental infection","volume":"6","author":"Mukherjee","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0159","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.4049\/jimmunol.1400710","article-title":"Imipramine exploits histone deacetylase 11 to increase the IL-12\/IL-10 ratio in macrophages infected with antimony-resistant Leishmania donovani and clears organ parasites in experimental infection","volume":"193","author":"Mukherjee","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0160","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1645\/GE-3489.1","article-title":"Selective action of fluoroquinolones against intracellular amastigotes of Leishmania (Viannia) panamensis in vitro","volume":"91","author":"Romero","year":"2005","journal-title":"J Parasitol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0161","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijantimicag.2011.03.004","article-title":"Antiprotozoal compounds: state of the art and new developments","volume":"38","author":"Astelbauer","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0162","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.drudis.2013.08.005","article-title":"Novel therapeutic strategies for treatment of visceral leishmaniasis","volume":"18","author":"Jain","year":"2013","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0163","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijpddr.2014.02.002","article-title":"Drug repurposing and human parasitic protozoan diseases","volume":"4","author":"Andrews","year":"2014","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0164","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2007.01.016","article-title":"Treatment of acute Old World cutaneous leishmaniasis: a systematic review of the randomized controlled trials","volume":"57","author":"Khatami","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0165","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/infdis\/165.3.528","article-title":"Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala","volume":"165","author":"Navin","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0166","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0002-9343(90)90292-L","article-title":"Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis","volume":"89","author":"Saenz","year":"1990","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0167","doi-asserted-by":"crossref","first-page":"e0006225","DOI":"10.1371\/journal.pntd.0006225","article-title":"Failure of fluconazole in treating cutaneous leishmaniasis caused by Leishmania guyanensis in the Brazilian Amazon: an open, nonrandomized phase 2 trial","volume":"12","author":"Francesconi","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0168","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1017\/S0031182007002600","article-title":"The anti-schistosomal drug praziquantel is an adenosine antagonist","volume":"134","author":"Angelucci","year":"2007","journal-title":"Parasitology"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0169","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ijantimicag.2006.12.018","article-title":"Praziquantel binds Schistosoma mansoni adult worm actin","volume":"29","author":"Tallima","year":"2007","journal-title":"Int. J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0170","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejmech.2014.07.007","article-title":"New praziquantel derivatives containing NO-donor furoxans and related furazans as active agents against Schistosoma mansoni","volume":"12","author":"Guglielmo","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0171","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cbpa.2007.05.031","article-title":"Chemotherapy of schistosomiasis: present and future","volume":"11","author":"Caffrey","year":"2007","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0172","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/jac\/dkt491","article-title":"The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer)","volume":"69","author":"Olliaro","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0173","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1590\/S0074-02761989000500005","article-title":"Resistance of schistosomes to hycanthone and oxamniquine","volume":"84","author":"Cioli","year":"1989","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0174","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1590\/S0034-89101978000100013","article-title":"Linhagem humana de Schistosoma mansoni resistente a esquistossomicidas","volume":"12","author":"Dias","year":"1978","journal-title":"Rev Sa\u00fade P\u00fablica"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0175","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1128\/AAC.47.5.1487-1495.2003","article-title":"Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials","volume":"47","author":"Utzinger","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0176","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.3390\/ph11010015","article-title":"Drug repurposing for schistosomiasis: combinations of drugs or biomolecules","volume":"11","author":"Gouveia","year":"2018","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0177","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.bmcl.2011.11.108","article-title":"Synthesis of new praziquantel analogues: potential candidates for the treatment of schistosomiasis","volume":"22","author":"Sadhu","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0178","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1016\/j.bmcl.2007.05.063","article-title":"Praziquantel derivatives I: modification of the aromatic ring","volume":"17","author":"Ronketti","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0179","doi-asserted-by":"crossref","first-page":"9163","DOI":"10.3390\/molecules18089163","article-title":"Synthesis and SAR studies of praziquantel derivatives with activity against Schistosoma japonicum","volume":"18","author":"Wang","year":"2013","journal-title":"Molecules"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0180","doi-asserted-by":"crossref","first-page":"e112163","DOI":"10.1371\/journal.pone.0112163","article-title":"An artemisinin derivative of praziquantel as an orally active antischistosomal agent","volume":"9","author":"Dong L Duan","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0181","first-page":"335","article-title":"Efficacy of a new Hoffmann-La Roche compound (Ro 15-5458) against Schistosoma mansoni (Gezira strain, Sudan) in vervet monkeys (Cercopithecus aethiops)","volume":"40","author":"Sulaiman","year":"1989","journal-title":"Trop Med Parasitol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0182","first-page":"391","article-title":"Effect of a combination of the new antischistosomal drug Ro 15-5458 and praziquantel on different strains of Schistosoma mansoni infected mice","volume":"50","author":"Kamel","year":"2000","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0183","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00436-009-1371-7","article-title":"Current chemotherapy arsenal for schistosomiasis mansoni: alternatives and challenges","volume":"104","author":"Abdul-Ghani","year":"2009","journal-title":"Parasitol Res"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0184","doi-asserted-by":"crossref","first-page":"e01586","DOI":"10.1128\/mBio.01586-16","article-title":"Origins of combination therapy for tuberculosis: lessons for future antimicrobial development and application","volume":"8","author":"Kerantzas","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0185","first-page":"2789","article-title":"Combination antiretroviral therapy for HIV infection","volume":"57","author":"Maenza","year":"1998","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0186","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nrd4573","article-title":"Malaria medicines: a glass half full?","volume":"14","author":"Wells","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0187","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijpddr.2014.07.002","article-title":"Repurposing drugs for the treatment and control of helminth infections","volume":"4","author":"Panic","year":"2014","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0188","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00436-013-3649-z","article-title":"Dihydroartemisinin: a new story of an old drug against Schistosoma mansoni infection","volume":"113","author":"Li","year":"2014","journal-title":"Parasitol Res"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0189","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1756-3305-3-108","article-title":"Heme and blood-feeding parasites: friends or foes?","volume":"3","author":"Toh","year":"2010","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0190","first-page":"165","article-title":"Dosage trial of a combination of oxamniquine and praziquantel in the treatment of schistosomiasis in Zimbabwean schoolchildren","volume":"32","author":"Creasey","year":"1986","journal-title":"Cent Afr J Med"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0191","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1021\/ar100070k","article-title":"Heme as trigger and target for trioxane-containing antimalarial drugs","volume":"43","author":"Meunier","year":"2010","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0192","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0020-7519(01)00297-1","article-title":"The potential of artemether for the control of schistosomiasis","volume":"31","author":"Utzinger","year":"2001","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0193","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.phrs.2016.02.017","article-title":"Antischistosomal activity of artemisinin derivatives in vivo and in patients","volume":"110","author":"Saeed","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0194","first-page":"5","article-title":"Comparative cure rates of artesunate-praziquantel combination and praziquantel monotherapy in the control of urinary schistosomiasis among \u201cAlmajiri\u201d school children in Sokoto, Nigeria","volume":"5","author":"Yunusa","year":"2016","journal-title":"Int Res J Basic Clin Stud"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0195","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.tmaid.2008.06.006","article-title":"Schistosomicidal activity of the antimalarial drug, mefloquine, in Schistosoma mansoni-infected mice","volume":"6","author":"Van Nassauw","year":"2008","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0196","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00436-010-2080-y","article-title":"Effect of mefloquine administered orally at single, multiple, or combined with artemether, artesunate, or praziquantel in treatment of mice infected with Schistosoma japonicum","volume":"108","author":"Xiao","year":"2011","journal-title":"Parasitol Res"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0197","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0065-308X(10)73008-6","article-title":"The drugs we have and the drugs we need against major helminth infections","volume":"73","author":"Keiser","year":"2010","journal-title":"Adv Parasitol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0198","doi-asserted-by":"crossref","first-page":"466","DOI":"10.4103\/2141-9248.139270","article-title":"Fixed dose combination of arterolane and piperaquine: a newer prospect in antimalarial therapy","volume":"4","author":"Patil","year":"2014","journal-title":"Ann Med Health Sci Res"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0199","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.actatropica.2014.12.005","article-title":"Efficacy of Synriam\u2122, a new antimalarial combination of OZ277 and piperaquine, against different developmental stages of Schistosoma mansoni","volume":"143","author":"Mossallam","year":"2015","journal-title":"Acta Trop"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0200","doi-asserted-by":"crossref","first-page":"737","DOI":"10.4155\/fmc.15.31","article-title":"Re-positioning protein-kinase inhibitors against schistosomiasis","volume":"7","author":"Gelmedin","year":"2015","journal-title":"Future Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0201","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pt.2010.09.001","article-title":"Piggy-backing the concept of cancer drugs for schistosomiasis treatment: a tangible perspective?","volume":"27","author":"Dissous","year":"2011","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0202","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ijpara.2010.01.007","article-title":"Imatinib has a fatal impact on morphology, pairing stability and survival of adult Schistosoma mansoni in vitro","volume":"40","author":"Beckmann","year":"2010","journal-title":"Int J Parasitol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0203","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1590\/0074-0276130207","article-title":"Imatinib activity on Schistosoma mansoni","volume":"108","author":"Katz","year":"2013","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0204","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2174\/1386207319666160506123921","article-title":"Natural products as a source for antileishmanial and antitrypanosomal agents","volume":"19","author":"Scotti","year":"2016","journal-title":"Comb Chem High Throughput Screen"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0205","doi-asserted-by":"crossref","first-page":"460","DOI":"10.2174\/1568026616666160824110141","article-title":"Flavonoids and Chagas' disease: the story so far!","volume":"17","author":"Nabavi","year":"2017","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0206","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1039\/c0np00069h","article-title":"Natural products and Chagas\u2019 disease: a review of plant compounds studied for activity against Trypanosoma cruzi","volume":"28","author":"Izumi","year":"2011","journal-title":"Nat Prod Rep"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0207","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.phytochem.2010.10.006","article-title":"Phenolic analogs of the N,C-coupled naphthylisoquinoline alkaloid ancistrocladinium A, from Ancistrocladus cochinchinensis (Ancistrocladaceae), with improved antiprotozoal activities","volume":"72","author":"Bringmann","year":"2011","journal-title":"Phytochemistry"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0208","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1021\/np5006554","article-title":"Antitrypanosomal quinoline alkaloids from the roots of Waltheria indica","volume":"77","author":"Cretton","year":"2014","journal-title":"J Nat Prod"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0209","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111877","article-title":"Hit-to-lead optimization of novel 2-alkylaminomethylquinoline derivatives as anti-Chagas agents","volume":"186","author":"Muscia","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0210","doi-asserted-by":"crossref","first-page":"9714","DOI":"10.3390\/molecules16119714","article-title":"Trypanocidal activity of oxoaporphine and pyrimidine-\u03b2-carboline alkaloids from the branches of Annona foetida Mart.(Annonaceae)","volume":"16","author":"Costa","year":"2011","journal-title":"Molecules"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0211","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.exppara.2007.08.015","article-title":"Trypanosoma cruzi: antiprotozoal activity of parthenolide obtained from Tanacetum parthenium (L.) Schultz Bip. (Asteraceae, Compositae) against epimastigote and amastigote forms","volume":"118","author":"Izumi","year":"2008","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0212","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.actatropica.2008.11.008","article-title":"Biological activity of 1,2,3,4-tetrahydro-betacarboline-3-carboxamides against Trypanosoma cruzi","volume":"110","author":"Valdez","year":"2009","journal-title":"Acta Trop"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0213","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1021\/np1008043","article-title":"In vitro and in vivo trypanocidal activity of flavonoids from Delphinium staphisagria against Chagas disease","volume":"74","author":"Marin","year":"2011","journal-title":"J Nat Prod"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0214","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.bmcl.2019.04.020","article-title":"Structure-activity relationship study of antitrypanosomal chalcone derivatives using multivariate analysis","volume":"29","author":"Gomes","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2019.152827","article-title":"Coumarins isolated from Calophyllum brasiliense produce ultrastructural alterations and affect in vitro infectivity of Trypanosoma cruzi","volume":"61","author":"Rodr\u00edguez-Hern\u00e1ndez","year":"2019","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0216","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1021\/np100348x","article-title":"Antiprotozoal steroidal saponins from the marine sponge Pandaros acanthifolium","volume":"73","author":"Regalado","year":"2010","journal-title":"J Nat Prod"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0217","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103276","article-title":"Antiprotozoal activities of marine polyether triterpenoids","volume":"92","author":"D\u00edaz-Marrero","year":"2019","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0218","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1021\/acs.jnatprod.9b00632","article-title":"(-)-Epigallocatechin 3-O-gallate as a new approach for the treatment of visceral leishmaniasis","volume":"82","author":"Inacio","year":"2019","journal-title":"J Nat Prod"},{"issue":"2","key":"10.1016\/j.ijantimicag.2020.105906_bib0219","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.exppara.2007.04.015","article-title":"Trypanosoma cruzi: in vitro and in vivo antiproliferative effects of epigallocatechin gallate (EGCg)","volume":"117","author":"Guida","year":"2007","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0220","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1128\/AAC.37.12.2550","article-title":"Licochalcone A, a novel antiparasitic agent with potent activity against human pathogenic protozoan species of Leishmania","volume":"37","author":"Chen","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0221","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1128\/AAC.38.6.1339","article-title":"Antileishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani","volume":"38","author":"Chen","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0222","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1128\/AAC.43.7.1776","article-title":"Improvement of in vitro and in vivo antileishmanial activities of 2\u00b4,6\u00b4-dihydroxy-4\u00b4-methoxychalcone by entrapment in poly(D,L-lactide) nanoparticles","volume":"43","author":"Torres-Santos","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0223","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/835910","article-title":"Natural products: insights into leishmaniasis inflammatory response","volume":"2015","author":"Rodrigues","year":"2015","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0224","doi-asserted-by":"crossref","first-page":"e3321","DOI":"10.1371\/journal.pntd.0003321","article-title":"Th1-Biased immunomodulation and therapeutic potential of Artemisia annua in murine visceral leishmaniasis","volume":"9","author":"Islamuddin","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0225","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1365-3083.2008.02219.x","article-title":"An alkaloid extract of evanta, traditionally used as anti-leishmania agent in Bolivia, inhibits cellular proliferation and interferon-gamma production in polyclonally activated cells","volume":"69","author":"Calla-Magarinos","year":"2009","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0226","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/md202055","article-title":"Identification of renieramycin A as an antileishmanial substance in a marine sponge Neopetrosia sp","volume":"2","author":"Nakao","year":"2004","journal-title":"Mar Drugs"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0227","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0031-9422(02)00361-8","article-title":"Abietane diterpenoids and triterpenoic acids from Salvia cilicica and their antileishmanial activities","volume":"61","author":"Tan","year":"2002","journal-title":"Phytochemistry"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0228","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1021\/np0497088","article-title":"Bisnortriterpenes from Salacia m adagascariensis","volume":"68","author":"Thiem","year":"2005","journal-title":"J Nat Prod"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0229","doi-asserted-by":"crossref","first-page":"E4536","DOI":"10.3390\/molecules24244536","article-title":"Antileishmanial compounds isolated from Psidium guajava L. using a metabolomic approach","volume":"24","author":"Phakeovilay","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0230","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.exppara.2019.02.013","article-title":"Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis","volume":"199","author":"Ara\u00fajo","year":"2019","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0231","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.1038\/s41598-019-42273-z","article-title":"A semi-synthetic neolignan derivative from dihydrodieugenol B selectively affects the bioenergetic system of Leishmania infantum and inhibits cell division","volume":"9","author":"Amaral","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0232","doi-asserted-by":"crossref","DOI":"10.1590\/1678-9199-jvatitd-2019-0008","article-title":"Antileishmanial activity and immunomodulatory effect of secosubamolide, a butanolide isolated from Nectandra oppositifolia (Lauraceae)","volume":"25","author":"Costa-Silva","year":"2019","journal-title":"J Venom Anim Toxins Incl Trop Dis"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0233","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/jac\/dkp170","article-title":"Activity of physalins purified form Physalins angulata in vitro and in vivo models of cutaneous leishmaniasis","volume":"64","author":"Guimar\u00e3es","year":"2009","journal-title":"J Antim Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0234","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.phytochem.2012.06.012","article-title":"Sterols with antileishmanial activity isolated from the roots of Pentalinon andrieuxii","volume":"82","author":"Pan","year":"2012","journal-title":"Phytochemistry"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0235","doi-asserted-by":"crossref","first-page":"801","DOI":"10.4155\/fmc.15.23","article-title":"Natural products with antischistosomal activity","volume":"7","author":"Moraes","year":"2015","journal-title":"Future Med Chem"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0236","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1055\/s-0033-1350732","article-title":"In vitro evaluation of schistosomicidal activity of essential oil of Mentha x villosa and some of its chemical constituents in adult worms of Schistosoma mansoni","volume":"79","author":"Matos-Rocha","year":"2013","journal-title":"Planta Med"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0237","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.3390\/molecules20021872","article-title":"Natural products as leads in schistosome drug discovery","volume":"20","author":"Neves","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0238","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1055\/s-0032-1327832","article-title":"In vitro schistosomicidal activity of balsaminol F and karavilagenin C","volume":"78","author":"Ramalhete","year":"2012","journal-title":"Planta Med"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0239","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1128\/AAC.05371-11","article-title":"In vivo activity of aryl ozonides against Schistosoma species","volume":"56","author":"Keiser","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0240","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1590\/0074-0276108052013011","article-title":"Antischistosomal activity of a calcium channel antagonist on schistosomula and adult Schistosoma mansoni worms","volume":"108","author":"Silva-Moraes","year":"2013","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0241","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.exppara.2010.08.021","article-title":"Schistosoma mansoni: in vitro schistosomicidal activity of piplartine","volume":"127","author":"Moraes","year":"2011","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0242","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.exppara.2012.07.004","article-title":"Schistosoma mansoni: in vitro schistosomicidal activity and tegumental alterations induced by piplartine on schistosomula","volume":"132","author":"Moraes","year":"2012","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0243","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00436-008-1311-y","article-title":"In vitro schistosomicidal activity of curcumin against Schistosoma mansoni adult worms","volume":"104","author":"Magalh\u00e3es","year":"2009","journal-title":"Parasitol Res"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0244","article-title":"Molluscicidal and cercaricidal activities of curcumin on Biomphalaria glabrata and Schistosoma mansoni cercariae","author":"Matos","year":"2019","journal-title":"Pest Manag Sci"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0245","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1007\/s00436-011-2790-9","article-title":"Curcumin treatment provides protection against Trypanosoma cruzi infection","volume":"110","author":"Nagajyothi","year":"2012","journal-title":"Parasitol Res"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0246","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.phymed.2013.08.012","article-title":"\u03b2-Lapachone: a naphthoquinone with promising antischistosomal properties in mice","volume":"21","author":"Aires","year":"2014","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0247","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.exppara.2014.04.010","article-title":"Ultrastructural analysis of \u03b2-lapachone-induced surface membrane damage in male adult Schistosoma mansoni BH strain worms","volume":"142","author":"Aires","year":"2014","journal-title":"Exp Parasitol"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0248","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s13071-019-3566-9","article-title":"The antioxidants resveratrol and N-acetylcysteine enhance anthelmintic activity of praziquantel and artesunate against Schistosoma mansoni","volume":"12","author":"Gouveia","year":"2019","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.ijantimicag.2020.105906_bib0249","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ijantimicag.2017.01.033","article-title":"Targeting Leishmania amazonensis amastigotes through macrophage internalisation of a hydroxymethylnitrofurazone nanostructured polymeric system","volume":"50","author":"Monteiro","year":"2017","journal-title":"Int J Antimicrob Agents"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920300455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920300455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:34:46Z","timestamp":1760376886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920300455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":249,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0924857920300455"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105906","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Searching for drugs for Chagas disease, leishmaniasis and schistosomiasis: a review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105906","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105906"}}